Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of Sunday, August 23, 2026.
Forward PE Ratio (N/A) = Close Price ($46.74) / Consensus Forward EPS ($22.08)
FORWARD PE RATIO
N/A
Novo Nordisk A/S
Market Cap
$207.55B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Novo Nordisk A/S (NVO) | $207.55B | N/A |
| Abbott Laboratories (ABT)vs › | $201.83B | 21.14 |
| Gilead Sciences, Inc. (GILD)vs › | $181.42B | N/A |
| Thermo Fisher Scientific Inc. (TMO)vs › | $233.85B | 25.06 |
| Amgen Inc. (AMGN)vs › | $237.11B | 19.04 |
| Pfizer Inc. (PFE)vs › | $159.98B | 9.44 |
| AstraZeneca PLC (AZN)vs › | $257.41B | 16.21 |
| Danaher Corporation (DHR)vs › | $153.85B | 25.74 |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $139.10B | 29.24 |
| Bristol-Myers Squibb Company (BMY)vs › | $136.88B | 9.67 |
Trailing P/E
11.5
reported TTM EPS
Forward P/E
N/A
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $22.08 implies +443.8% EPS growth vs the reported trailing $4.06.
At today's $46.74 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| Fiscal year end |
|---|
| Consensus EPS |
|---|
| Estimate range |
|---|
| Analysts |
|---|
| Implied P/E |
|---|
| 2026-12-31 | $22.08 | $19.88 – $23.18 | 6 | 2.1x |
| 2027-12-31 | $21.80 | $20.12 – $23.62 | 7 | 2.1x |
| 2028-12-31 | $23.58 | $21.54 – $26.80 | 4 | 2.0x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
